Harrow (HROW) Change in Receivables (2014 - 2026)
Harrow's (HROW) quarterly Change in Receivables came in at -$9.8 million in Q1 2026, up 74.92% year-on-year from -$5.6 million in Q1 2025, and down 129.6% quarter-over-quarter from $33.2 million in Q4 2025.
Harrow (HROW) Change in Receivables (2014 - 2026) Analysis & Trends
Harrow's Change in Receivables history runs 13 years deep, the most recent figure standing at -$9.8 million for Q1 2026.
- On a quarterly basis, Change in Receivables rose 74.92% year-over-year to -$9.8 million in Q1 2026; TTM through Mar 2026 was $24.4 million, a 50.73% decrease from a year earlier, with the FY2025 full-year figure at -$5.0 million, down 106.24% from the prior year.
- Change in Receivables eased to -$9.8 million in Q1 2026 per HROW's latest filing, from $33.2 million in the prior quarter.
- Across five years, Change in Receivables topped out at $62.8 million in Q4 2024 and bottomed at -$39.2 million in Q1 2025.
- The 5-year median for Change in Receivables is $1.5 million (2022), against an average of $5.7 million.
- Across the five-year window, Change in Receivables surged 5080.0% in 2023 and sank 366.84% in 2025, its largest moves.
- Year by year, Change in Receivables stood at -$449000.0 in 2022, then surged by 4121.6% to $18.1 million in 2023, then jumped by 247.67% to $62.8 million in 2024, then slumped by 47.09% to $33.2 million in 2025, then plunged by 129.6% to -$9.8 million in 2026.
- Per Business Quant, the three latest HROW Change in Receivables figures stand at -$9.8 million (Q1 2026), $33.2 million (Q4 2025), and -$1.0 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | -78.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 106.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -621.82 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | -38.20 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 126.30 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 81.40 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | - |
| 10 | Harrow | 1.56 Bn | 1.47 Bn | 27.05 Mn | -9.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -9.83 Mn |
| Mar 31, 2026 | -9.83 Mn |
| Dec 31, 2025 | 33.22 Mn |
| Dec 31, 2025 | 33.22 Mn |
| Sep 30, 2025 | -1.01 Mn |
| Sep 30, 2025 | -1.01 Mn |
| Jun 30, 2025 | 1.99 Mn |
| Jun 30, 2025 | 1.99 Mn |
| Mar 31, 2025 | -39.20 Mn |
| Mar 31, 2025 | -39.20 Mn |
| Dec 31, 2024 | 62.78 Mn |
| Dec 31, 2024 | 62.78 Mn |
| Sep 30, 2024 | 1.82 Mn |
| Sep 30, 2024 | 1.82 Mn |
| Jun 30, 2024 | 24.03 Mn |
| Jun 30, 2024 | 24.03 Mn |
| Mar 31, 2024 | -8.40 Mn |
| Mar 31, 2024 | -8.40 Mn |
| Dec 31, 2023 | 18.06 Mn |
| Dec 31, 2023 | 18.06 Mn |